低剂量茶碱治疗生物质相关COPD的有效性:LODOT-BCOPD随机对照试验方案
LODOT-BCOPD是一项在乌干达中部开展的随机双盲安慰剂对照试验,纳入110例中重度生物质相关COPD患者,比较每日一次低剂量茶碱(200 mg缓释剂)与安慰剂共52周的疗效。主要结局为12个月时SGRQ评分变化,并评估成本效果。
要点
- 低剂量茶碱200 mg缓释剂每日一次口服,用于资源有限地区生物质相关COPD。
- 主要结局为12个月时圣乔治呼吸问卷评分变化。
- 将计算QALY评估成本效果,并监测茶碱水平与炎症生物标志物。
核心结论
- 该试验旨在评估低剂量茶碱改善生物质相关COPD患者呼吸症状的临床疗效与成本效果。
研究设计与样本
- 随机、双盲、安慰剂对照试验,在乌干达中部纳入110例中重度COPD参与者。
- 纳入标准包括年龄40至80岁、每日生物质暴露、支气管舒张后FEV1/FVC低于全球肺倡议混合种族参考人群第5百分位、GOLD B-D级。
- 干预为每日一次低剂量茶碱200 mg缓释剂(Unicontin-E)或安慰剂,持续52周。
- 所有参与者接受COPD自我管理教育和沙丁胺醇吸入剂作为缓解用药。
关键数值与推荐
- 主要结局为12个月时SGRQ评分变化。
- 基线及每6个月测量SGRQ和EQ-5D。
- 基线、1个月和6个月评估家庭空气污染水平、血清炎症生物标志物(纤维蛋白原、hs-CRP)和茶碱水平。
- 通过EQ-5D计算QALY评估成本效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: COPD is a leading cause of death globally, with the majority of morbidity and mortality occurring in low- and middle-income country (LMIC) settings. While tobacco-smoke exposure is the most important risk factor for COPD in high-income settings, household air pollution from biomass smoke combustion is a leading risk factor for COPD in LMICs. Despite the high burden of biomass smoke-related COPD, few studies have evaluated the efficacy of pharmacotherapy in this context. Currently recommended inhaler-based therapy for COPD is neither available nor affordable in most resource-limited settings. Low-dose theophylline is an oral, once-a-day therapy, long used in high-income countries (HICs), which has been proposed for the management of COPD in LMICs in the absence of inhaled steroids and/or bronchodilators. The Low-dose Theophylline for the Management of Biomass-Associated COPD (LODOT-BCOPD) trial investigates the clinical efficacy and cost-effectiveness of low-dose theophylline for the management of biomass-related COPD in a low-income setting. METHODS: LODOT-BCOPD is a randomized, double-blind, placebo-controlled trial to test the efficacy of low-dose theophylline in improving respiratory symptoms in 110 participants with moderate to severe COPD in Central Uganda. The inclusion criteria are as follows: (1) age 40 to 80 years, (2) full-time resident of the study area, (3) daily biomass exposure, (4) post-bronchodilator FEV1/FVC below the 5th percentile of the Global Lung Initiative mixed ethnic reference population, and (5) GOLD Grade B-D COPD. Participants will be randomly assigned to receive once daily low-dose theophylline (200 mg ER, Unicontin-E) or placebo for 52 weeks. All participants will receive education about self-management of COPD and rescue salbutamol inhalers. We will measure health status using the St. George's Respiratory Questionnaire (SGRQ) and quality of life using the EuroQol-5D (EQ-5D) at baseline and every 6 months. In addition, we will assess household air pollution levels, serum inflammatory biomarkers (fibrinogen, hs-CRP), and theophylline levels at baseline, 1 month, and 6 months. The primary outcome is change in SGRQ score at 12 months. Lastly, we will assess the cost-effectiveness of the intervention by calculating quality-adjusted life years (QALYs) from the EQ-5D. TRIAL REGISTRATION: ClinicalTrials.gov NCT03984188 . Registered on June 12, 2019 TRIAL ACRONYM: Low-dose Theophylline for the Management of Biomass-Associated COPD (LODOT-BCOPD).
引用
- Siddharthan T, Pollard SL, Jackson P, et al. Effectiveness of low-dose theophylline for the management of biomass-associated COPD (LODOT-BCOPD): study protocol for a randomized controlled trial. Trials. 2021. PMID: 33726828. doi:10.1186/s13063-021-05163-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。